CDX Continues to negotiate a binding agreement for a business partnership with CD’X Post published:12/07/2020
CDX CD’X (held 7%) began commercial-marketing OISPSA test for the Cleveland Clinic Urology Department Post published:08/07/2020
CARDIACSENSE Cardiacsense (approx. 5.87%) – Starting an Experiment on the Smart Watch for Breathing Rhythm at Ichilov Hospital Post published:21/06/2020
CARDIACSENSE Cardiacsense Capital Raising Round (5.33%) – The Company Will Invest $ 250, Hold 5.87% of Equity Post published:15/06/2020
CARDIACSENSE Cardiacsence (approximately 6.16%) in exclusive distribution agreement for medical watches it develops Post published:27/05/2020
CARDIACSENSE Cardiacsense (6.16%), has signed an exclusive distribution deal to sell medical watches Post published:21/05/2020
CARDIACSENSE Cardiacsense (6.34%), signed two exclusive distribution agreements for the sale of medical watches Post published:12/05/2020
EFA IFA (9.09%), has received the right to grant permission from the Innovation Authority for the R&D project for a mobile blood test device Post published:06/05/2020
